Aurelien Sutra Del Galy

Aurelien Sutra Del Galy

Auto-generated profile, based on publicly available information

Aurelien Sutra Del Galy

Hematology–Transplantation, AP-HP Hospital St Louis, Paris, France

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 August 2019 in Blood Advances
Verified
Journal Article
Open access
PDF file
SPSimona Pagliuca
Simona Pagliuca
DMDavid Michonneau
David Michonneau
FFFlore Sicre de Fontbrune
Flore Sicre de Fontbrune
AGAurélien Sutra del Galy
Aurélien Sutra del Galy
AXAliénor Xhaard
Aliénor Xhaard
GSGérard Socie
Gérard Socie
Endothelial cell (EC) activation has been suspected of triggering a group of rare and dismal complications that can occur after allogeneic hematopoietic stem cell transplantation (HSCT). Capillary leak syndrome, engraftment syndrome, transplant-associated microangiopathy, diffuse alveolar hemorrhage, and idiopathic pneumonia syndrome are the main nosological entities. Post-HSCT endotheliitis can be triggered by chemotherapy, infections, and calcineurin inhibitors, but allogeneic reactivity is claimed to be the common denominator. Endothelial damages are thought to activate several deleterious pathways (proapoptotic, procoagulant, proinflammatory) and can lead to multiorgan failure; however, clinical manifestations of each syndrome overlap, and their relationship with graft-versus-host disease could be minimal. The lack of well-defined diagnostic criteria does not allow for a clear-cut comparison in the current literature. Therapeutic efforts have been made to intercept the pathogenic mechanisms leading to EC dysfunction, but remission rates and survival remain mostly unsatisfactory. In this article, we have reviewed the incidence, clinical features, and treatment approaches of EC activation syndromes, and we plead for the development of internationally accepted standard definitions.

24 December 2021 in Science Immunology
Verified
Journal Article
Closed access
AGAurélien Sutra Del Galy
Aurélien Sutra Del Galy
SMSilvia Menegatti
Silvia Menegatti
JFJaime Fuentealba
Jaime Fuentealba
FLFrancesca Lucibello
Francesca Lucibello
LPLaetitia Perrin
Laetitia Perrin
LMLaurie Menger
Laurie Menger
Inactivation of SOCS1 optimizes adoptive T cell therapy including human CAR-T cell composition and efficacy.

17 August 2022 in Blood Advances
Verified
Journal Article
Open access
PDF file
Marie RobinMarie Robin
Marie Robin
RPRaphael Porcher
Raphael Porcher
DMDavid Michonneau
David Michonneau
LTLaetitia Taurines
Laetitia Taurines
FFFlore Sicre de Fontbrune
Flore Sicre de Fontbrune
MSMarie-Hélène Schlageter
Marie-Hélène Schlageter
Acute graft-versus-host disease (GVHD) is still the major contributor to comorbidities and mortality after allogeneic hematopoietic stem cell transplantation. The use of plasmatic biomarkers to predict early outcomes has been advocated in the past decade. The purpose of this prospective noninterventional study was to test the ability of panels including 7 biomarkers (Elafin, HGF, IL2RA, IL8, REG3, ST2, and TNFRI), to predict day 28 (D28) complete response to steroid, D180 overall survival, and D180 nonrelapse mortality (NRM). Using previous algorithms developed by the Ann Arbor/MAGIC consortium, 204 patients with acute GVHD were prospectively included and biomarkers were measured at GVHD onset for all of them. Initial GVHD grade and bilirubin level were significantly associated with all those outcomes. After adjustment on clinical variables, biomarkers were associated with survival and NRM. In addition to clinical variables, biomarkers slightly improved the prediction of overall survival and NRM (concordance and net reclassification indexes). The potential benefit of adding biomarkers panel to clinical parameters was also investigated by decision curve analyses. The benefit of adding biomarkers to clinical parameters was however marginal for the D28 nonresponse and mortality endpoints.

27 October 2023 in Science Immunology
Verified
Journal Article
Closed access
PBPierre-Emmanuel Bonté
Pierre-Emmanuel Bonté
CMChristina Metoikidou
Christina Metoikidou
SHSandrine Heurtebise-Chretien
Sandrine Heurtebise-Chretien
YAYago A. Arribas
Yago A. Arribas
AGAurélien Sutra Del Galy
Aurélien Sutra Del Galy
SASebastian Amigorena
Sebastian Amigorena
In chronic infections and cancer, T cells are exposed to prolonged antigen stimulation, resulting in loss of function (or exhaustion) and impairment of effective immunological protection. Exhausted T cells are heterogeneous and include early progenitors (Tpex) and terminally exhausted cells (Tex). Here, we used bulk and single-cell transcriptomics to analyze expression of transposable elements (TEs) in subpopulations of mouse and human CD8 + tumor-infiltrating T lymphocytes (TILs). We show that in mice, members of the virus-like murine VL30 TE family (mostly intact, evolutionary young ERV1s) are strongly repressed in terminally exhausted CD8 + T cells in both tumor and viral models of exhaustion. Tpex expression of these VL30s, which are mainly intergenic and transcribed independently of their closest gene neighbors, was driven by Fli1, a transcription factor involved in progression from Tpex to Tex. Immune checkpoint blockade (ICB) in both mice and patients with cancer increased TE expression (including VL30 in mice), demonstrating that TEs may be applicable as ICB response biomarkers. We conclude that expression of TEs is tightly regulated in TILs during establishment of exhaustion and reprogramming by ICB. Analyses of TE expression on single cells and bulk populations open opportunities for understanding immune cell identity and heterogeneity, as well as for defining cellular gene expression signatures and disease biomarkers.

25 June 2020 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
SPSimona Pagliuca
Simona Pagliuca
PPPedro Henrique Prata
Pedro Henrique Prata
AXAliénor Xhaard
Aliénor Xhaard
CFCamilla Frieri
Camilla Frieri
LGLivia Giannoni
Livia Giannoni
Marie RobinMarie Robin
Marie Robin

30 July 2020 in Leukemia
Verified
Journal Article
Closed access
PDF file
AGA. Sutra Del Galy
A. Sutra Del Galy
AMA. Marouf
A. Marouf
ERE. Raffoux
E. Raffoux
MRM. Robin
M. Robin
DMDavid Michonneau
David Michonneau
GSG. Socié
G. Socié